Lecap Asset Management Ltd. Has $1.88 Million Holdings in DexCom, Inc. $DXCM

Key Points

• Lecap Asset Management Ltd. reduced its holdings in DexCom, Inc. by 62.1% in the second quarter, now owning 21,528 shares valued at approximately $1.88 million.
• Multiple hedge funds have increased their stakes in DexCom, with significant investments including a new stake worth $554.9 million by Nuveen LLC in the first quarter.
• DexCom reported earnings of $0.48 per share in its latest quarterly results, exceeding estimates and reflecting a 15.2% revenue increase compared to the same quarter last year.

Lecap Asset Management Ltd. lessened its holdings in shares of DexCom, Inc. (NASDAQ:DXCM - Free Report) by 62.1% during the 2nd quarter, according to its most recent filing with the Securities and Exchange Commission. The firm owned 21,528 shares of the medical device company's stock after selling 35,344 shares during the quarter. Lecap Asset Management Ltd.'s holdings in DexCom were worth $1,879,000 as of its most recent SEC filing.

Several other hedge funds have also added to or reduced their stakes in DXCM. Nuveen LLC acquired a new stake in DexCom during the 1st quarter worth $554,893,000. Jennison Associates LLC raised its stake in DexCom by 37.7% during the 1st quarter. Jennison Associates LLC now owns 10,523,246 shares of the medical device company's stock worth $718,632,000 after buying an additional 2,879,489 shares during the period. Massachusetts Financial Services Co. MA raised its stake in DexCom by 171.0% during the 1st quarter. Massachusetts Financial Services Co. MA now owns 3,194,829 shares of the medical device company's stock worth $218,175,000 after buying an additional 2,015,971 shares during the period. Federated Hermes Inc. raised its stake in DexCom by 2,371.4% during the 1st quarter. Federated Hermes Inc. now owns 1,994,732 shares of the medical device company's stock worth $136,220,000 after buying an additional 1,914,019 shares during the period. Finally, UBS AM A Distinct Business Unit of UBS Asset Management Americas LLC raised its stake in DexCom by 22.6% during the 1st quarter. UBS AM A Distinct Business Unit of UBS Asset Management Americas LLC now owns 10,123,525 shares of the medical device company's stock worth $691,336,000 after buying an additional 1,868,241 shares during the period. Institutional investors and hedge funds own 97.75% of the company's stock.

DexCom Price Performance

Shares of NASDAQ DXCM opened at $66.08 on Thursday. The stock has a market capitalization of $25.91 billion, a price-to-earnings ratio of 45.89, a PEG ratio of 1.41 and a beta of 1.47. The business has a 50-day moving average of $77.16 and a 200-day moving average of $77.94. The company has a debt-to-equity ratio of 0.48, a current ratio of 1.52 and a quick ratio of 1.35. DexCom, Inc. has a fifty-two week low of $57.52 and a fifty-two week high of $93.25.

DexCom (NASDAQ:DXCM - Get Free Report) last announced its quarterly earnings data on Wednesday, July 30th. The medical device company reported $0.48 earnings per share for the quarter, beating the consensus estimate of $0.45 by $0.03. DexCom had a return on equity of 30.41% and a net margin of 13.29%.The company had revenue of $1.16 billion during the quarter, compared to analysts' expectations of $1.13 billion. During the same quarter last year, the company earned $0.43 EPS. DexCom's revenue for the quarter was up 15.2% compared to the same quarter last year. DexCom has set its FY 2025 guidance at EPS. As a group, sell-side analysts predict that DexCom, Inc. will post 2.03 earnings per share for the current fiscal year.

Analyst Ratings Changes

A number of research firms have issued reports on DXCM. Canaccord Genuity Group reiterated a "buy" rating and set a $106.00 target price on shares of DexCom in a report on Monday. Barclays increased their target price on DexCom from $93.00 to $98.00 and gave the stock an "equal weight" rating in a report on Wednesday, July 30th. Raymond James Financial increased their target price on DexCom from $99.00 to $102.00 and gave the stock a "strong-buy" rating in a report on Thursday, July 31st. Argus began coverage on DexCom in a report on Thursday, August 21st. They set a "buy" rating and a $100.00 target price for the company. Finally, Mizuho increased their target price on DexCom from $95.00 to $100.00 and gave the stock an "outperform" rating in a report on Wednesday, July 16th. Three research analysts have rated the stock with a Strong Buy rating, fourteen have issued a Buy rating and five have assigned a Hold rating to the company. According to MarketBeat.com, the stock currently has a consensus rating of "Moderate Buy" and an average price target of $98.32.

Insiders Place Their Bets

In related news, Director Mark G. Foletta sold 2,750 shares of DexCom stock in a transaction dated Friday, August 15th. The stock was sold at an average price of $81.06, for a total transaction of $222,915.00. Following the completion of the transaction, the director owned 51,121 shares in the company, valued at approximately $4,143,868.26. This trade represents a 5.10% decrease in their ownership of the stock. The transaction was disclosed in a document filed with the SEC, which is accessible through this hyperlink. Also, EVP Sadie Stern sold 1,466 shares of the firm's stock in a transaction that occurred on Thursday, September 4th. The stock was sold at an average price of $80.00, for a total transaction of $117,280.00. Following the sale, the executive vice president owned 105,223 shares of the company's stock, valued at $8,417,840. This trade represents a 1.37% decrease in their ownership of the stock. The disclosure for this sale can be found here. Over the last ninety days, insiders have sold 6,849 shares of company stock worth $564,733. Company insiders own 0.32% of the company's stock.

DexCom Company Profile

DexCom, Inc, a medical device company, focuses on the design, development, and commercialization of continuous glucose monitoring (CGM) systems in the United States and internationally. The company provides its systems for use by people with diabetes, as well as for use by healthcare providers. Its products include Dexcom G6 and Dexcom G7, integrated CGM systems for diabetes management; Dexcom Share, a remote monitoring system; Dexcom Real-Time API, which enables authorized third-party software developers to integrate real-time CGM data into their digital health apps and devices; and Dexcom ONE, that is designed to replace finger stick blood glucose testing for diabetes treatment decisions.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.